GlassScriptPhysician profile
Gabriel Alvarez
NPI 1144576190
$37,050.26
in general payments reported to CMS, 2019-2025
23 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,088 · 2022: $6,194 · 2023: $25K · 2024: $649 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $4,604 · Travel and Lodging: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,882.50 |
| Food and Beverage | $4,604.04 |
| Travel and Lodging | $2,281.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20,912.76 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $10,776.59 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,214.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $635.79 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $580.21 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.37 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $402.01 | 2021-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $374.70 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $329.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $279.15 | 2021-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $196.82 | 2021-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $176.82 | 2025 | Jornay Pm |
| Corium, LLC | $144.72 | 2024-2025 | Azstarys |
| Neos Therapeutics, LP | $75.13 | 2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $72.11 | 2025 | Aplenzin, Wellbutrin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $70.46 | 2021-2022 | |
| Lundbeck LLC | $62.13 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $60.58 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $52.96 | 2024-2025 | Cobenfy |
| Uswm, LLC | $43.55 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.87 | 2025 | Rexulti |
| Indivior INC. | $35.33 | 2022 | |
| Merck Sharp & Dohme LLC | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.